# Industry BlueBook

Pharma Services: Development

September 2020

The industry's authoritative information resource for valuations, M&A transactions, and Financings


# DASHBOARD<sup>1,2,3,4,5</sup>

| EV MULTIPLES                          |       |         |       |     |       |        |       |    |  |
|---------------------------------------|-------|---------|-------|-----|-------|--------|-------|----|--|
|                                       |       | REVENUE |       |     |       | EBITDA |       |    |  |
|                                       | LTM   | %∆      | FTM   | %∆  | LTM   | %∆     | FTM   | %∆ |  |
| Development Technology & Info Systems | 17.9x | 0%      | 15.0x | 0%  | 21.4x | NM     | 42.9x | 0% |  |
| Development Clinical Services         | 3.1x  | 2%      | 3.5x  | 17% | 17.9x | NM     | 17.0x | NM |  |
| Development Laboratory Services       | 4.6x  | NM      | 4.5x  | 0%  | 21.2x | 1%     | 19.8x | NM |  |


| M&A DEALS & FINANCINGS                |     |     |            |     |     |               |            |    |  |
|---------------------------------------|-----|-----|------------|-----|-----|---------------|------------|----|--|
|                                       |     | [   | DEAL COUNT |     |     | VOLUME (\$MM) |            |    |  |
|                                       | M&A | %∆  | FINANCINGS | %∆  | M&A | %∆            | FINANCINGS | %∆ |  |
| Development Technology & Info Systems | 0   | NM  | 6          | 50% | 0   | NM            | 285        | NM |  |
| Development Clinical Services         | 4   | 33% | 5          |     | 0   |               | 117        | NM |  |
| Development Laboratory Services       | 2   | 0%  | 4          | NM  | 0   | NM            | 124        | NM |  |

- 1. Enterprise value (EV) equals equity market value (market capitalization) plus debt, plus preferred stock, minus cash and cash equivalents
- 2. Deals counted once in total if included in multiple segments
- 3. LTM = last twelve months; FTM = forward twelve months
- 4.  $\%\Delta$  percent change month over month
- 5. NM Not Meaningful


## 12 Month Deal Count M&A




## 12 Month Volume M&A (\$MM)



### 12 Month Deal Count Financings



### 12 Month Volume Financings (\$MM)



# M&A ACTIVITY

## **DEALS BY SEGMENT**

#### Development

| Clinical Service | Lab Se              | Lab Services     |         |                       |
|------------------|---------------------|------------------|---------|-----------------------|
| Data Services    | Regulatory Services | Clinical Support | In Vivo | Bioanalytical<br>Labs |
| Trial Execution  |                     |                  |         |                       |

## U.S. DEALS BY STATE



## WORLDWIDE DEALS BY COUNTRY



| SELECTED TRANSACTIONS |                     |  |                              |                         |   |                |  |  |  |
|-----------------------|---------------------|--|------------------------------|-------------------------|---|----------------|--|--|--|
| Announced Da          | ite Segment         | Sub-Segment  | Target Company               | Geography               | Selected Buyers                                     | Size<br>(\$mm) |  |  |  |
| 9/24/2020             | Lab Services        | Bioanalytical  | XenoGesis Ltd.               | United Kingdom          | Sygnature Discovery Limited                         | -              |  |  |  |
| 9/22/2020             | Clinical<br>Service | Clinical Support   | ProPharma Group, Inc.        | United States           | Odyssey Investment Partners, LLC                    | -              |  |  |  |
| 9/16/2020             | Clinical<br>Service | Trial Execution<br>Regulatory<br>Services<br>Data Services | ClinArt International FZ LLC | United Arab<br>Emirates | CTI Clinical Trial and Consulting<br>Services, Inc. | -              |  |  |  |
| 9/15/2020             | Clinical<br>Service | Data Services  | Array Biostatistics LLC      | United States           | Cato Research                                       | -              |  |  |  |

| Announced Da | ate Segment                         | Sub-Segment   | Target Company                             | Geography     | Selected Buyers | Size<br>(\$mm) |
|--------------|-------------------------------------|---|--|---------------|-----------------|----------------|
| 9/1/2020     | Clinical<br>Service<br>Lab Services | Trial Execution<br>Regulatory<br>Services<br>Data Services<br>In Vivo | North American Science<br>Associates, Inc. | United States | ArchiMed SAS    | -              |

# **FINANCINGS**

## **DEALS BY SEGMENT**

## Development

| Dev Tech                        |   | Clinical Service |                        | Lab Services |              |  |
|---------------------------------|---|------------------|------------------------|--------------|--------------|--|
| Operations Technology           | Data Science Tools                            | Data Services    | Regulatory<br>Services | In Vivo      | Genomics Lab |  |
| Clinical Trial Data Acquisition | Regulatory &<br>Safety<br>Trial<br>Technology | Trial Execution  | Clinical Support       | Other Lal    | o Services   |  |

## U.S. DEALS BY STATE



## WORLDWIDE DEALS BY COUNTRY



| SELECTED TRANSACTIONS |  |   |           |  |                |  |  |  |  |
|-----------------------|--|---|-----------|--|----------------|--|--|--|--|
| Closed Date Segment   | Sub-Segment  | Target Company                                  | Geography | Selected Investors   | Size<br>(\$mm) |  |  |  |  |
| 9/28/2020 Dev Tech    | Operations Tech<br>Regulatory & Safety<br>Tech<br>Data Acquisition<br>Data Science Tools | Zhejiang Taimei Medical<br>Technology Co., Ltd. | China     | SB China Venture Capital, Haitong Capital Co., Ltd., Morningside Venture Capital, BioTrack Capital, Beijing Yuanyuan Capital Investment Co., Ltd., Omniscience Capital, China Soft Capital Management Group Co., Ltd., Ivy Capital, Yunfeng Capital, Ivy Capital |                |  |  |  |  |

| Closed Date | Segment                         | Sub-Segment   | Target Company                                   | Geography         | Selected Investors   | Size<br>(\$mm) |
|-------------|---------------------------------|---|--|-------------------|--|----------------|
| 9/24/2020   | Clinical<br>Service             | Trial Execution<br>Regulatory Services<br>Data Services | Within3, Inc.                                    | United States     | Insight Venture Partners LLC,<br>Silversmith Management, L.P.  | 100.0          |
| 9/24/2020   | Clinical<br>Service             | Trial Execution<br>Regulatory Services<br>Data Services | Shanghai Bestudy Medical<br>Technology Co., Ltd. | China             | Loyal Valley Capital, Shenzhen<br>Qianhai Tri Wise Capital<br>Management Co., Ltd.   | 2.2            |
| 9/23/2020   | Lab Services                    | Genomics<br>Other Lab Services                          | Obio Technology (Shanghai)<br>Corp.,Ltd.         | China             | The Morningside Group Limited,<br>GP Capital Co., Ltd, GP Capital Co.,<br>Ltd, Loyal Valley Capital, Sherpa<br>Venture Capital, BioTrack Capital,<br>Shanghai Lingang Innovation<br>Center   | 44.2           |
| 9/21/2020   | Lab Services                    | Genomics  | GeneWerk GmbH                                    | Germany           | Ampersand Capital Partners   | -              |
| 9/21/2020   | Dev Tech                        | Operations Tech   | TriNetX, Inc.                                    | United States     | Carlyle Group L.P. (NasdaqGS:CG)   | -              |
| 9/15/2020   | Lab Services                    | In Vivo   | Beijing Biocytogen Co., Ltd                      | China             | 3E Bioventures Capital, SDIC<br>Venture Capital Co., Ltd., CMB<br>International Capital Corporation,<br>Investment Arm, China Life Private<br>Equity Investment Co., Ltd., China<br>Life Private Equity Investment Co.,<br>Ltd., LYZZ Capital, China Soft<br>Capital Management Group Co.,<br>Ltd. | 21.1           |
| 9/11/2020   | Lab Services                    | In Vivo   | GemPharmatech Co.,Ltd                            | China             | Hillhouse Capital Management,<br>Ltd., Sequoia Capital China, VI<br>Ventures, Dangdai International<br>Group Co., Ltd., TF Capital   | 58.5           |
| 9/11/2020   | Clinical<br>Service             | Clinical Support  | Xintong Pharmacy                                 | China             | Undisclosed  | 14.6           |
| 9/10/2020   | Clinical<br>Service             | Trial Execution Data Services                           | ProSciento, Inc.                                 | United States     | 1315 Capital LLC   | -              |
| 9/3/2020    | Dev Tech                        | Operations Tech   | uMotif Limited                                   | United<br>Kingdom | Azini Capital Partners LLP,<br>AlbionVC  | 6.6            |
| 9/3/2020    | Dev Tech                        | Operations Tech   | Advanced Digital Innovation (UK) Ltd.            | United<br>Kingdom | Mercia Fund Management Ltd.  | 2.7            |
| 9/2/2020    | Dev Tech                        | Data Acquisition  | Biofourmis Singapore Pte. Ltd.                   | Singapore         | EDB Investments Pte. Ltd., Sequoia<br>Capital India Advisors Private<br>Limited, MassMutual Ventures<br>LLC, Sofina Société Anonyme<br>(ENXTBR:SOF), SoftBank<br>Investment Advisers (UK) Limited  | 100.0          |
| 9/1/2020    | Dev Tech<br>Clinical<br>Service | Operations Tech<br>Data Science Tools<br>Data Services  | CluePoints INC                                   | United States     | Summit Partners, L.P.  | -              |

# PUBLIC MARKETS<sup>1</sup>

| DEVELOPMENT TECHNOLOGY & INFO SYSTEMS |               |                  |        |        |        |        |  |  |  |
|---------------------------------------|---------------|------------------|--------|--------|--------|--------|--|--|--|
| Company Name                          | Geography     | Enterprise Value | xRever | nue    | xEBITE | )A     |  |  |  |
| Company Name                          | Geography     | (\$mm)           | LTM EV | FTM EV | LTM EV | FTM EV |  |  |  |
| IQVIA Holdings Inc.                   | United States | 42,074           | 3.9x   | 3.6x   | 21.4x  | 17.0x  |  |  |  |
| Veeva Systems Inc.                    | United States | 40,973           | 31.9x  | 26.5x  | NM     | 68.8x  |  |  |  |
| Mean                                  |               | 41,524           | 17.9x  | 15.0x  | 21.4x  | 42.9x  |  |  |  |
| Median                                |               | 41,524           | 17.9x  | 15.0x  | 21.4x  | 42.9x  |  |  |  |

| DEVELOPMENT CLINICAL SERVICES                  |               |                  |          |        |        |        |  |  |  |
|--|---------------|------------------|----------|--------|--------|--------|--|--|--|
| Company Name                                   | Geography     | Enterprise Value | xRevenue |        | xEBIT  | DA     |  |  |  |
| Company Name                                   | Geography     | (\$mm)           | LTM EV   | FTM EV | LTM EV | FTM EV |  |  |  |
| Charles River Laboratories International, Inc. | United States | 13,307           | 4.8x     | 4.5x   | 19.8x  | 18.5x  |  |  |  |
| CMIC HOLDINGS Co., Ltd.                        | Japan         | 434              | 0.6x     | 0.6x   | 5.6x   | 6.8x   |  |  |  |
| ICON Public Limited Company                    | Ireland       | 9,900            | 3.6x     | 3.5x   | 19.7x  | 20.2x  |  |  |  |
| IQVIA Holdings Inc.                            | United States | 42,074           | 3.9x     | 3.6x   | 21.4x  | 17.0x  |  |  |  |
| Linical Co., Ltd.                              | Japan         | 181              | 1.8x     | 1.7x   | 16.0x  | 11.0x  |  |  |  |
| Medpace Holdings, Inc.                         | United States | 3,903            | 4.4x     | 3.9x   | 22.9x  | 17.7x  |  |  |  |
| PPD, Inc.                                      | United States | 16,834           | 4.1x     | 3.6x   | 21.9x  | 18.5x  |  |  |  |
| PRA Health Sciences, Inc.                      | United States | 7,816            | 2.5x     | 2.4x   | 16.1x  | 14.7x  |  |  |  |
| Seiko Epson Corporation                        | Japan         | 4,246            | 0.5x     | 0.5x   | 4.6x   | 4.8x   |  |  |  |
| Shin Nippon Biomedical Laboratories, Ltd.      | Japan         | 384              | 2.7x     | NM     | 8.6x   | NM     |  |  |  |
| Syneos Health, Inc.                            | United States | 8,253            | 1.8x     | 1.7x   | 12.7x  | 12.5x  |  |  |  |
| WuXi AppTec Co., Ltd.                          | China         | 36,464           | 17.4x    | 13.4x  | 74.5x  | 50.5x  |  |  |  |
| Mean   |               | 11,983           | 4.0x     | 3.6x   | 20.3x  | 17.5x  |  |  |  |
| Median   |               | 8,035            | 3.1x     | 3.5x   | 17.9x  | 17.0x  |  |  |  |

| DEVELOPMENT LABORATORY SERVICES                |                     |                  |        |          |        |                 |  |  |  |
|--|---------------------|------------------|--------|----------|--------|-----------------|--|--|--|
| Company Name                                   | Geography           | Enterprise Value | xReve  | xRevenue |        | <sup>-</sup> DA |  |  |  |
| Company Name                                   | Cography            | (\$mm)           | LTM EV | FTM EV   | LTM EV | FTM EV          |  |  |  |
| Champions Oncology, Inc.                       | United States       | 117              | 3.4x   | 2.9x     | NM     | 65.0x           |  |  |  |
| Charles River Laboratories International, Inc. | United States       | 13,307           | 4.8x   | 4.5x     | 19.8x  | 18.5x           |  |  |  |
| Eurofins Scientific SE                         | Luxembourg          | 18,199           | 3.3x   | 3.0x     | 15.7x  | 13.7x           |  |  |  |
| Evotec SE                                      | Germany             | 4,270            | 7.7x   | 7.1x     | 33.8x  | 30.1x           |  |  |  |
| Frontage Holdings Corporation                  | United States       | 733              | 7.2x   | 5.7x     | 43.9x  | 24.0x           |  |  |  |
| ICON Public Limited Company                    | Ireland             | 9,900            | 3.6x   | 3.5x     | 19.7x  | 20.2x           |  |  |  |
| Joinn Laboratories (China) Co., Ltd.           | China               | 3,040            | 24.7x  | 20.1x    | NM     | 70.5x           |  |  |  |
| KNOTUS Co.,Ltd                                 | Korea (Republic of) | 161              | 3.4x   | NM       | 20.5x  | NM              |  |  |  |
| Medpace Holdings, Inc.                         | United States       | 3,903            | 4.4x   | 3.9x     | 22.9x  | 17.7x           |  |  |  |
| Personalis, Inc.                               | United States       | 739              | 10.0x  | 8.9x     | NM     | NM              |  |  |  |
| Pharmaron Beijing Co., Ltd. (SZSE:300759)      | China               | 11,293           | 17.8x  | 14.7x    | 70.2x  | 51.5x           |  |  |  |

| PPD, Inc.                                 | United States | 16,834 | 4.1x  | 3.6x  | 21.9x | 18.5x |
|---|---------------|--------|-------|-------|-------|-------|
| PRA Health Sciences, Inc.                 | United States | 7,816  | 2.5x  | 2.4x  | 16.1x | 14.7x |
| Selvita S.A.                              | Poland        | 189    | 7.4x  | 5.0x  | 34.3x | 19.4x |
| Shanghai Medicilon Inc.                   | China         | 1,491  | 19.8x | NM    | NM    | NM    |
| Shin Nippon Biomedical Laboratories, Ltd. | Japan         | 384    | 2.7x  | NM    | 8.6x  | NM    |
| Syneos Health, Inc.                       | United States | 8,253  | 1.8x  | 1.7x  | 12.7x | 12.5x |
| WuXi AppTec Co., Ltd.                     | China         | 36,464 | 17.4x | 13.4x | 74.5x | 50.5x |
| Mean                                      |               | 7,616  | 8.1x  | 6.7x  | 29.6x | 30.5x |
| Median                                    |               | 4,087  | 4.6x  | 4.5x  | 21.2x | 19.8x |
|   |               |        |       |       |       |       |

## RECENT CROSSTREE TRANSACTIONS

Crosstree Capital Partners provides mergers and acquisitions and financing advisory services exclusively to leading Health Sciences companies. Since inception, the firm has been a consistent leader within our focus areas, closing more than 100 successful transactions with companies ranging from private equity-backed consolidators to Fortune 500 publicly-traded companies. In the process, we have represented clients on five continents, and roughly 35% of our transactions have been cross-border.

















#### Contact Us

Shane Senior, CFA
Head of Pharma Services
813-774-4755
shane.senior@crosstreecapital.com
www.crosstreecapital.com

#### Locations

Tampa (Headquarters) 2701 North Rocky Point Dr Tampa, FL 33607 New York 420 Lexington Ave New York, NY 10170